Last Update 02 Apr 26

BANB: Future Execution On Project Pipeline Will Support CHF 80 Upside Potential

Narrative Update

Analyst price targets for Bachem Holding have shifted to a range of CHF 60 to CHF 80, with the upper end raised from CHF 75, as analysts reflect updated views on the company in their valuation work.

Analyst Commentary

Recent research updates on Bachem Holding point to a split in how analysts see the risk and reward around the stock, which feeds directly into the current CHF 60 to CHF 80 price target range.

Bullish Takeaways

Bullish analysts are comfortable valuing the shares toward the upper end of the current range, as reflected in the move to CHF 80, which signals confidence that the company can support a higher valuation over time.
Supportive views suggest that, at prices closer to CHF 60 to CHF 70, the risk or reward trade off may be seen as attractive relative to those higher targets.
The willingness to raise targets rather than hold them flat indicates that optimistic analysts see room for the company to execute against their existing investment cases rather than needing to trim expectations.
For investors, the CHF 80 target acts as an anchor for more optimistic scenarios around growth, margins or contract wins that could justify a richer multiple on future earnings.

Bearish Takeaways

Bearish analysts have reset expectations to CHF 60, which sits at the bottom of the current range and reflects a more cautious stance on how much investors should be willing to pay for the shares.
The lower target suggests concerns about execution risk, such as timing of projects or cost control, that could limit upside relative to more optimistic cases.
A neutral style rating, paired with a reduced target, points to a view that the stock may be fairly valued or even full at recent trading levels, with less room for re rating without clearer evidence of outperformance.
For more cautious investors, the CHF 60 level can be read as a reference point for downside scenarios if growth or profitability does not track the more positive assumptions embedded in higher targets.

What's in the News

Bachem Holding AG plans an Analyst or Investor Day event, giving you a chance to hear management discuss the business and outlook in more depth (Key Developments).
The company announced an annual dividend of CHF 0.4500 per share, with an ex date on May 4, 2026, a record date on May 5, 2026, and payment on May 6, 2026 (Key Developments).

Valuation Changes

Fair Value: CHF 78.3 is unchanged, indicating no shift in the central valuation estimate used in this model.
Discount Rate: edged up slightly from 4.684062% to 4.696014514019661%, a very small adjustment to the rate applied to future cash flows.
Revenue Growth: held steady at 24.756806091766226%, with no change in the assumed top line growth rate.
Net Profit Margin: remains effectively the same at 18.86584036873549%, with no revision to expected profitability.
Future P/E: is broadly unchanged, moving marginally from 26.458625x to 26.467689499158606x, indicating a stable earnings multiple assumption.

0 views

Key Takeaways

Significant expansion in large-scale manufacturing and process automation positions Bachem for outsized growth and improved margins amid rising demand for peptide and oligonucleotide drugs.
Strong long-term customer partnerships and leadership in advanced therapeutics offer recurring, less volatile revenue and structural advantage as biopharma outsourcing intensifies.
Large investment needs, currency risk, industry price pressures, and reliance on timely capacity expansion threaten Bachem's financial flexibility, margins, and future growth prospects.

Catalysts

About Bachem Holding

Provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide.What are the underlying business or industry changes driving this perspective?

Bachem's substantial investment in expanding large-scale manufacturing capacity-particularly with the new Building K expected to enter GMP production in 2025 and begin significant revenue contribution in 2026-positions the company to capture accelerating demand from high-growth peptide and oligonucleotide drug markets, supporting outsized future revenue growth.
The rapidly expanding pipeline of peptide and oligonucleotide therapeutics across multiple indications, including the massive projected growth in the anti-obesity market, provides strong, multi-year visibility for outsourcing demand; Bachem's leadership in these modalities and the current supply-demand imbalance offer the potential for sustained volume and pricing power, boosting both revenue and margins.
Continuous operational excellence initiatives, such as harmonization of processes across sites, implementation of shift work, network production, and increasing automation, are already delivering material cost efficiencies; these trends should drive further improvement in net margins and earnings as new capacity ramps.
The expansion of long-term customer partnerships-underscored by high visibility of prepayments from major pharma clients-aligns Bachem for recurring business, reduced revenue volatility, and consistent margin expansion as global biopharma intensifies outsourcing of complex molecule production.
Early, proactive investment in next-generation oligonucleotide manufacturing, with a healthy backlog of projects and clear order visibility, positions Bachem to benefit disproportionately as regulatory approvals increase and the global acceptance of these advanced therapeutics widens the addressable market, underpinning structural top-line growth.

Bachem Holding Earnings and Revenue Growth

Bachem Holding Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Bachem Holding's revenue will grow by 24.8% annually over the next 3 years.
Analysts assume that profit margins will shrink from 21.4% today to 18.9% in 3 years time.
Analysts expect earnings to reach CHF 254.6 million (and earnings per share of CHF 3.47) by about April 2029, up from CHF 148.8 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting CHF310.7 million in earnings, and the most bearish expecting CHF214.2 million.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 26.6x on those 2029 earnings, down from 33.6x today. This future PE is lower than the current PE for the GB Life Sciences industry at 33.6x.
Analysts expect the number of shares outstanding to grow by 0.21% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 4.7%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Significant ongoing and future CapEx requirements (including CHF 400+ million in 2025 and continued large-scale investments at multiple sites) could put sustained pressure on free cash flow and increase reliance on external debt financing, raising the risk of reduced financial flexibility and potentially dilutive equity needs if internal cash generation lags.
Heightened exposure to currency volatility, especially due to the strong Swiss franc and much of Bachem's revenue base in US dollars, is already impacting margins and net income (CHF 11 million FX loss in H1), and could weigh on future revenues and profitability if unfavorable exchange rate trends persist.
Intensifying industry-wide efficiency improvements and automation (both by Bachem and its competitors) could lead to pricing pressure on long-term customer contracts, reducing gross margins if cost savings are passed on to customers or if customers demand lower prices as the industry becomes more commoditized.
Heavy dependence on successful completion, regulatory approval, and commissioning of new manufacturing capacity (notably Building K and major US expansions) means that any delays, cost overruns, or regulatory setbacks could limit growth, lead to underutilization of assets, and pressure future earnings.
Persistent and rising operational and financing costs-including ramp-up costs for new facilities, increased personnel to support growth, and growing debt service-could erode net margins, especially if revenue growth slows, industry pricing pressure intensifies, or macroeconomic/FX headwinds worsen.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of CHF78.3 for Bachem Holding based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of CHF110.0, and the most bearish reporting a price target of just CHF46.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be CHF1.3 billion, earnings will come to CHF254.6 million, and it would be trading on a PE ratio of 26.6x, assuming you use a discount rate of 4.7%.
Given the current share price of CHF66.65, the analyst price target of CHF78.3 is 14.9% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Bachem Holding?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Building K Production Will Serve Peptide And Oligonucleotide Therapies